EXPLORE!

Vaginal Gel Promising in Preventing Common STIs

  661 Views

#Business And Medicine  #Infectious Diseases  #Obstetrics and Gynecology  #Pathology and Lab Medicine  #Pharmacist 

eMediNexus    11 April 2021

An investigational vaginal gel was found to significantly decrease urogenital chlamydia and gonorrhea in women at high risk for infection, in comparison with placebo, in a randomized trial published in the American Journal of Obstetrics and Gynecology.

EVO100, an investigational antimicrobial, bioadhesive vaginal gel, contains L-lactic acid, citric acid, and potassium bitartrate. Investigators assessed the efficacy and safety of this gel in the AMPREVENCE study in the prevention of chlamydia and gonorrhea.EVO100 led to a significant reduction in STI incidence for both types of STIs. Chlamydia trachomatis infection rate among EVO100 users was 4.8% compared to 9.7% in placebo users. In the Neisseria gonorrhoeae-analysis–eligible women, infection rates were 0.7%, compared to 3.2% in the placebo group… (Medscape)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.